Related Experiment Video
Updated: Jun 16, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Considerations for commonly prescribed medications by dermatologists in patients on immune checkpoint inhibitors
Carolyn Rachofsky1, Mei Hong Liu1, Angelica D'Aiello2
1Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
Journal of the American Academy of Dermatology
|June 13, 2026
Summary
Dermatologists must understand how common medications affect cancer immunotherapy. This review highlights drugs like antibiotics and corticosteroids that can alter immune checkpoint inhibitor (ICI) efficacy and patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) have transformed cancer therapy.
- Dermatologists frequently manage conditions in patients receiving ICIs, including immune-related adverse events (irAEs).
- Many common dermatologic treatments may impact ICI efficacy.
Purpose of the Study:
- To raise awareness among healthcare professionals about how medications prescribed by dermatologists can affect immunotherapy response.
- To review existing evidence on the interactions between common dermatologic drugs and ICIs.
Main Methods:
- Literature review of studies investigating the impact of various medications on ICI efficacy.
- Focus on antibiotics, systemic corticosteroids, Janus kinase (JAK) inhibitors, biologics, and other immunomodulators.
- Analysis of potential consequences for patients undergoing cancer immunotherapy.
Main Results:
- Certain medications commonly used in dermatology practice can significantly alter the efficacy of immune checkpoint inhibitors.
- Evidence suggests interactions with antibiotics, systemic corticosteroids, JAK inhibitors, and biologics.
- Understanding these interactions is crucial for managing irAEs and other dermatologic conditions in ICI-treated patients.
Conclusions:
- Improved awareness of drug interactions is essential for optimizing the care of cancer patients receiving immunotherapy.
- Informed management strategies for irAEs and dermatologic conditions can improve patient outcomes.
- Collaboration between oncologists and dermatologists is key to navigating these complex treatment scenarios.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...